Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Melina Sophie KurteAnn-Cathrine SiefenFlorian JakobsBastian von TresckowHans Christian ReinhardtFlorian KronPublished in: European journal of haematology (2023)
Using the EF approach, the currently most cost-effective interventions (based on cost-effectiveness ratios) in the indication of R/R DLBCL were identified to guide international reimbursement decisions.